PSMA‐NB (277 ± 11 nm) enabled specific tumor uptake by PSMA‐expressing tumors and selective retention, thus significantly extending duration of ultrasound signal enhancement compared to nontargeted NBs (approximately two‐fold longer). This evidence concerns the gene FOLH1 and neoplasm.